Tricuspid valve disease affects the gateway between the upper and lower chambers on the right side of the heart, disrupting the normal flow of blood through this vital organ. When this valve malfunctions, the heart works harder to move blood forward, and over time, this extra strain can lead to serious complications. Understanding the available treatment options, from medications to advanced surgical procedures and emerging therapies tested in clinical research, can help patients and their families navigate this challenging condition with greater confidence.

Understanding Treatment Goals and Approaches

Treatment for tricuspid valve disease focuses on several important goals that work together to improve a patient’s health and well-being. The primary aim is to relieve troubling symptoms such as fatigue, swelling in the legs and abdomen, shortness of breath, and the uncomfortable pulsing sensation some people feel in their chest or neck. Beyond symptom relief, treatment seeks to prevent the heart from becoming permanently damaged, maintain the heart’s ability to pump blood effectively, and ultimately improve both the length and quality of a patient’s life.^[1][2]

The specific treatment path depends heavily on how severe the valve disease is, what caused it in the first place, and the overall health of the patient. For instance, someone with only mild leakage might need nothing more than regular monitoring, while a person with severe disease and significant symptoms may require surgical intervention. The patient’s age, the presence of other medical conditions, and how well their heart is functioning all play crucial roles in determining the best approach.^[6]

Modern medicine offers a range of standard treatments that have been approved by medical societies and used successfully for many years. These include medications to manage symptoms and underlying conditions, as well as surgical procedures to repair or replace the damaged valve. At the same time, researchers are actively investigating new therapies through clinical trials. These studies test innovative approaches that may offer benefits to patients who cannot undergo traditional surgery or who need more effective treatment options.^[2][9]

The choice between monitoring, medication, and surgery is not always straightforward. Healthcare providers must carefully weigh multiple factors, including whether the valve disease is primary (meaning the valve itself is damaged) or secondary (meaning the valve is structurally normal but not working properly due to another heart condition). They must also consider whether the right ventricle has become enlarged, whether pulmonary hypertension is present, and how the patient’s symptoms affect their daily activities and overall quality of life.^[2][8]

Standard Medical Treatment

When tricuspid valve disease is diagnosed, especially in mild to moderate cases or when surgery is not immediately necessary, medications form the foundation of treatment. These drugs do not fix the valve itself, but they help manage the symptoms and address underlying conditions that may be causing or worsening the valve problem.^[6][8]

Diuretics, commonly known as water pills, are among the most frequently prescribed medications for tricuspid valve disease. These drugs help the body eliminate excess fluid that accumulates due to the backward flow of blood through the leaky valve. When blood pools in the right side of the heart, pressure builds up in the veins throughout the body, causing fluid to leak into surrounding tissues. This results in swelling of the legs, ankles, feet, and abdomen. Diuretics work by increasing urine production, which removes this excess fluid and reduces swelling. While these medications can significantly improve comfort and reduce symptoms, they require careful management because they can affect kidney function and electrolyte balance in the body.^[6][15]

For patients whose tricuspid valve disease is secondary to heart failure, additional medications become important. ACE inhibitors and aldosterone antagonists are drugs that help the heart pump more efficiently and can slow the progression of heart failure. ACE inhibitors work by relaxing blood vessels, making it easier for the heart to pump blood forward. Aldosterone antagonists help prevent further damage to the heart muscle and reduce fluid retention. These medications have been shown to improve survival and quality of life in patients with heart failure, which is often an underlying cause of functional tricuspid regurgitation.^[10]

When tricuspid valve disease is caused by infection, such as infective endocarditis, antibiotics become a critical part of treatment. These medications target the bacteria that have settled on the valve and are causing damage. In cases of rheumatic heart disease, which results from inadequately treated strep throat infections, long-term antibiotic therapy may be necessary to prevent further valve damage.^[2][4]

For patients with pulmonary hypertension (high blood pressure in the lung circulation) contributing to tricuspid valve problems, specific medications may be prescribed to lower this pressure. By reducing the strain on the right side of the heart, these drugs can help slow the progression of valve disease and improve symptoms.^[4]

Patients with irregular heart rhythms, such as atrial fibrillation, may require medications called antiarrhythmics to help control their heart rate and rhythm. Additionally, blood thinners may be prescribed to reduce the risk of blood clots forming in the enlarged right atrium, which could lead to stroke or other serious complications.^[12]

The duration of medical therapy varies greatly from patient to patient. Some people may take these medications for months or years while being closely monitored for disease progression. Others may use medications as a bridge to surgery, helping to stabilize their condition before undergoing valve repair or replacement. Regular follow-up appointments are essential to assess how well the medications are working and to adjust doses as needed.^[6][21]

Common side effects of these medications include increased urination and potential dehydration from diuretics, low blood pressure and dizziness from ACE inhibitors, and changes in kidney function that require regular blood tests to monitor. Patients should report any new or worsening symptoms to their healthcare provider promptly, as medication adjustments may be necessary to balance benefits against side effects.^[21]

Surgical Treatment Options

When tricuspid valve disease becomes severe and causes significant symptoms or heart damage, surgical intervention may be necessary. The traditional approach involves open-heart surgery, during which a surgeon directly accesses the heart to repair or replace the damaged valve. This type of surgery requires making an incision in the chest, stopping the heart temporarily, and using a heart-lung machine to maintain blood circulation during the procedure.^[6][8]

Tricuspid valve repair is generally preferred over replacement when possible because it preserves the patient’s own valve and reduces the risk of complications. The most common repair technique is called annuloplasty, which involves implanting a synthetic ring around the base of the valve. This ring tightens the enlarged opening, allowing the valve leaflets to close more completely and reducing backward blood flow. The surgeon may also perform additional repairs on the valve leaflets themselves, such as stitching torn sections or removing excess tissue that prevents proper closure.^[6][12]

Tricuspid valve replacement becomes necessary when the valve is too damaged to repair effectively. During replacement surgery, the diseased valve is completely removed and replaced with either a mechanical valve made from durable materials like metal and carbon, or a biological valve made from animal tissue. Mechanical valves last longer but require patients to take blood-thinning medications for the rest of their lives to prevent blood clots. Biological valves do not require long-term blood thinners but may need to be replaced after ten to fifteen years as the tissue deteriorates.^[6]

Medical guidelines recommend considering surgery for patients with severe tricuspid regurgitation who are experiencing symptoms or whose right ventricle is progressively enlarging. Surgery is also often recommended when tricuspid valve disease is discovered during operations for other heart valve problems, particularly mitral valve disease. Research has shown that addressing tricuspid regurgitation at the time of left-sided valve surgery can prevent the need for additional operations later.^[9]

However, open-heart surgery carries significant risks, especially for older patients or those with advanced heart failure, severe pulmonary hypertension, or multiple other health problems. The recovery period is lengthy, typically requiring several weeks to months before patients can return to normal activities. Complications can include infection, bleeding, stroke, and in some cases, death. The decision to proceed with surgery must carefully balance these risks against the potential benefits of valve repair or replacement.^[2][8]

For patients who are too sick or frail for traditional open-heart surgery, newer minimally invasive options have emerged. Some surgeons now perform valve repair through smaller incisions between the ribs, using specialized instruments and cameras to guide the procedure. Robotic surgery is another advanced technique that allows surgeons to operate with greater precision through tiny openings in the chest. These approaches can reduce pain, shorten hospital stays, and speed recovery compared to traditional open-heart surgery.^[12]

Transcatheter Treatments: A New Frontier

Recent years have witnessed remarkable progress in developing catheter-based procedures that can repair or replace the tricuspid valve without open-heart surgery. These innovative approaches, collectively known as transcatheter interventions, represent a significant advance for patients who previously had few treatment options due to high surgical risk.^[11][12]

Transcatheter edge-to-edge repair (TEER) has emerged as an important treatment option for severe tricuspid regurgitation. The most studied device for this procedure is the TriClip G4, which received FDA approval in April 2024. This device works by bringing the valve leaflets closer together, reducing the gap through which blood can leak backward. The procedure involves inserting a thin, flexible tube called a catheter through a large vein in the leg or neck and carefully guiding it up to the heart using advanced imaging technology. Once positioned correctly, the clip is deployed to grasp the valve leaflets and hold them in a better position for closing.^[11][20]

Clinical trials have provided important evidence about the effectiveness of TriClip TEER. The TRILUMINATE study, published in a major medical journal in March 2023, compared patients treated with the TriClip device to those receiving only medications. The study involved 65 medical centers, including leading institutions in the United States, and followed patients for an extended period. Results showed that 87% of patients who underwent the TriClip procedure experienced a significant reduction in the severity of their tricuspid regurgitation. These patients also reported improvements in their symptoms and quality of life compared to those receiving medications alone.^[11]

The mechanism of action for TEER is straightforward yet elegant. By clipping the valve leaflets together at strategic points, the device reduces the size of the opening through which blood can flow backward. This allows the heart to work more efficiently, reducing the buildup of pressure and fluid that causes symptoms. The procedure typically takes between one and three hours and requires only one or two small incisions where the catheter is inserted. Most patients can leave the hospital within a few days and resume normal activities much sooner than they would after open-heart surgery.^[11][20]

At the two-year follow-up point, patients who received the TriClip showed a 28% reduction in the risk of hospitalization for heart failure compared to those treated with medications alone. This finding is particularly significant because repeated hospitalizations not only affect quality of life but also indicate worsening heart function and increased mortality risk.^[20]

Transcatheter tricuspid valve replacement (TTVR) represents another innovative approach for patients with severe disease. Instead of repairing the existing valve, this procedure involves implanting a new valve through a catheter, similar to procedures already established for the aortic valve. Recent studies have shown that catheter-based valve replacement can effectively treat severe tricuspid regurgitation in high-risk patients who would otherwise have a poor prognosis.^[13]

These transcatheter procedures are particularly valuable for patients with impaired right ventricular function, enlarged valve openings, or left ventricular ejection fraction below 40% who are not suitable candidates for traditional surgery. They may also benefit patients with significant scarring or damage from previous heart surgeries, those with multiple medical conditions that increase surgical risk, and older adults who would struggle with the lengthy recovery required after open-heart surgery.^[10][12]

Multiple transcatheter devices are currently being studied in clinical trials at various stages of development. These trials typically progress through several phases. Phase I trials focus primarily on safety, testing new devices in a small number of patients to ensure they do not cause unacceptable harm. Phase II trials expand to larger groups and begin evaluating whether the device effectively treats the condition as intended. Phase III trials compare the new treatment directly against standard care in large populations to definitively establish its benefits and risks. Many of these trials are taking place at leading medical centers across the United States, Europe, and other regions.^[9][12]

The preliminary results from various clinical trials have been encouraging, showing improvements in clinical parameters such as reduced regurgitation severity, decreased heart chamber sizes, and better exercise capacity. Safety profiles have generally been positive, with complication rates comparable to or better than those seen with traditional surgery in high-risk patients. However, longer follow-up periods are needed to fully understand how durable these repairs remain over time.^[10][13]

Patient eligibility for transcatheter procedures depends on multiple factors assessed by a specialized heart team. This team typically includes interventional cardiologists who perform catheter-based procedures, cardiac surgeons, imaging specialists, and other experts who work together to determine the best treatment approach. They carefully review echocardiogram results, assess the patient’s overall health status, evaluate the anatomy of the tricuspid valve and surrounding structures, and discuss the patient’s goals and preferences before making recommendations.^[11][12]

Most Common Treatment Methods

• Medications
  • Diuretics (water pills) to remove excess fluid and reduce swelling in the legs, ankles, feet, and abdomen caused by blood backing up through the leaky valve
  • ACE inhibitors to help the heart pump more efficiently by relaxing blood vessels, particularly important when heart failure contributes to valve disease
  • Aldosterone antagonists to prevent further heart damage and reduce fluid retention in patients with underlying heart failure
  • Antiarrhythmic medications to control irregular heart rhythms such as atrial fibrillation, which often occurs alongside tricuspid valve disease
  • Blood thinners to prevent blood clots from forming in enlarged heart chambers
  • Antibiotics when infection causes or contributes to valve damage
• Surgical Valve Repair
  • Annuloplasty using a synthetic ring implanted around the valve base to tighten the enlarged opening and help leaflets close properly
  • Direct repair of valve leaflets through stitching torn sections or removing excess tissue
  • Minimally invasive approaches through smaller incisions between ribs using specialized instruments
  • Robotic-assisted surgery for greater precision through tiny chest openings
• Surgical Valve Replacement
  • Mechanical valves made from durable materials requiring lifelong blood-thinning medication
  • Biological valves from animal tissue not requiring long-term blood thinners but needing replacement after ten to fifteen years
• Transcatheter Edge-to-Edge Repair (TEER)
  • TriClip G4 device delivered through a catheter in the leg or neck vein to clip valve leaflets together
  • Minimally invasive procedure reducing symptoms and hospitalizations in high-risk patients not suitable for open-heart surgery
  • Shorter recovery time compared to traditional surgery with most patients leaving the hospital within a few days
• Transcatheter Valve Replacement (TTVR)
  • New valve implanted through catheter without open-heart surgery for patients with severe disease
  • Option for patients with impaired heart function, enlarged valve openings, or previous heart surgeries